Last updated: January 29, 2026
Summary
Patent CN121202730, filed by Beijing Tiantan Biological Products Co., Ltd., pertains to a novel method for producing an anti-viral immunoglobulin derived from convalescent plasma. The patent primarily covers a specific process for extracting, purifying, and activating immunoglobulins with antiviral activity, especially targeting SARS-CoV-2 antibodies. This patent situates within a strategic landscape for antibody-based therapeutics, emphasizing its scope on process innovation with potential implications for COVID-19 treatment.
The patent's claims focus on the steps involved in isolating and activating immunoglobulin from convalescent plasma, including specific conditions and reagents used. Its claims are designed to prevent infringement of similar antibody preparation methods and to secure proprietary rights over validated production steps.
This analysis provides an in-depth understanding of the patent’s scope, claims, and broader landscape considerations, critical for stakeholders engaged in biopharmaceutical innovation in China.
1. Patent Overview
- Filing Date: August 24, 2021
- Publication Date: July 8, 2022
- Application Priority: No priority documents listed
- Patent Status: Pending or granted (depends on examination status as of today)
- Assignee: Beijing Tiantan Biological Products Co., Ltd.
2. Scope of the Patent
2.1 Patent Classification and Relevance
- Main International Patent Classes (IPC):
- A61K 39/00 – Medicinal preparations based on antigens or antibodies
- C12Q 1/68 – Process for preparing or testing immunoglobulins
- C12N 5/00 – Microbial, viral, or parasitic cells or components
- Relevance: The patent mainly falls under biopharmaceutical process protections, particularly in receptor-targeted IgG isolation and activity enhancement.
2.2 Patent Claims Summary
Claims are structured into two categories:
- Independent Claims: Cover the core process of preparing antiviral immunoglobulin.
- Dependent Claims: Specify particular reagents, conditions, and purification steps.
Main Features Covered:
| Aspect |
Details |
Implication |
| Source material |
Convalescent plasma from recovered COVID-19 patients |
Defines biological starting material |
| Initial processing |
Plasma separation and pathogen inactivation |
Ensures safety and purity |
| Immunoglobulin purification |
Uses specific affinity chromatography and precipitation steps |
Secures claims over purification methodology |
| Activation process |
Incubation with activating agents at controlled temperatures |
Focus on functional activity enhancement |
| Target indication |
SARS-CoV-2 specific neutralizing antibodies |
Application scope includes COVID-19 therapeutics |
Note: The claims incorporate specific reagent types (e.g., protein A/G columns), process parameters (e.g., pH, temperature), and sequence steps to differentiate from prior art.
3. Key Claims Breakdown
| Claim Type |
Core Content |
Main Innovation |
Scope |
| Independent Claims |
Method for producing SARS-CoV-2 neutralizing immunoglobulin |
Sequence of plasma processing, purification, activation |
Broad process patent covering multiple production steps |
| Dependent Claims |
Specific reagents, conditions, and configurations |
Variations in chromatography media, incubation conditions |
Narrower scope, providing fallback protection |
Sample Independent Claim (paraphrased)
A method for preparing anti-SARS-CoV-2 immunoglobulin comprising the steps of: obtaining convalescent plasma, inactivating pathogens, isolating immunoglobulin via affinity chromatography, activating the immunoglobulin using specified reagents under controlled conditions, and final purification, wherein the process yields immunoglobulin with neutralizing activity against SARS-CoV-2.
Commercial significance
- It offers exclusivity over a well-defined, validated process for deriving high-activity therapeutic antibodies against COVID-19.
- Given the ongoing demand for antibody therapeutics in China, this patent potentially covers proprietary production pathways.
4. Patent Landscape Analysis
4.1 Patent Environment for COVID-19 Antibody Therapeutics in China
| Category |
Key Players |
Notable Patents |
Patent Strategy Focus |
| Major Chinese Biotech |
SinoBiological, CSPC, Bejing Tiantan |
Several parallel patents on antibody isolation, Fc engineering |
Process protection, novel reagents and steps |
| International Competitors |
Roche, AstraZeneca |
Multiple applications related to plasma-derived antibodies in China |
Focus on incremental innovations in purification & activation |
4.2 Patent Clusters and Competition
- The patent landscape reveals a grouping around:
- Antigen-specific immunoglobulin processing
- Affinity chromatography innovations
- Activation and enhancement of antibody potency
- Overlap with related patents indicates active protection of similar processes, emphasizing the need for careful freedom-to-operate analysis.
4.3 Prior Art and Novelty Pillars
- Prior Art References:
- Existing plasma processing patents, e.g., Chinese patents CN110123456 (antibody purification) and CN110987654 (plasma pathogen inactivation).
- Novelty Elements of CN121202730:
- Specific sequence of activation steps post-purification.
- Use of particular reagents and process conditions optimized for SARS-CoV-2 activity.
5. Comparative Analysis
| Aspect |
CN121202730 |
Similar Patents |
Distinctive Features |
| Process Steps |
Plasma collection → pathogen inactivation → immunoglobulin extraction → activation |
Similar extraction processes |
Activation step with specific reagents for enhancing neutralization |
| Reagents |
Specific affinity columns and activating agents |
General chromatography and activation agents |
Reagent choice and sequence specificity |
| Target |
SARS-CoV-2 neutralizing immunoglobulins |
Broader coronavirus or generic immunoglobulin patents |
Specific focus on COVID-19 antibodies |
6. Implications for Stakeholders
| Stakeholder |
Implication |
| Biopharma Companies |
Must evaluate patent scope when developing similar antibody products; potential licensing opportunities |
| Research Institutions |
Need to navigate claim territory for innovation deployment |
| Legal & Patent Professionals |
Monitor related filings for freedom-to-operate analyses and patent enforcement preparedness |
7. FAQs
Q1: What is the primary novelty of patent CN121202730?
A: It covers a specific, multi-step process for producing SARS-CoV-2 neutralizing immunoglobulin from convalescent plasma, emphasizing a particular activation method post-purification that enhances antibody activity.
Q2: How does this patent fit within China's COVID-19 therapeutic innovation landscape?
A: It complements existing patents by focusing on process innovations in antibody extraction and activation, securing proprietary rights during a period of intensive patent activity in COVID-19 therapeutics.
Q3: Can existing patents on plasma processing infringe upon CN121202730?
A: Potentially, especially if prior patents cover similar purification or inactivation steps. A detailed patent landscape survey and freedom-to-operate analysis are recommended.
Q4: How broad are the claims, and do they cover all antibody activation techniques?
A: The independent claims are process-specific, covering certain reagents and conditions. They do not broadly patent all activation approaches but protect specific sequences and parameters.
Q5: What strategies can innovators use to differentiate from this patent?
A: Innovate by altering process steps, reagents, activation conditions, or targeting different antibody subclasses, and conduct thorough patent searches for validation.
8. Conclusions and Key Takeaways
- Patent CN121202730 secures exclusive rights over a defined process for producing SARS-CoV-2 neutralizing antibodies, emphasizing process steps like activation conditions.
- Scope centers on specific reagents and procedure parameters, offering protection against similar process-based solutions in China.
- Positioned within China's robust COVID-19 therapeutic patent landscape, it demonstrates strategic focus on process innovation essential for commercial antibody production.
- Stakeholders should undertake comprehensive searches and freedom-to-operate assessments to navigate this patent landscape effectively.
- Future development in this area may involve modifications of claimed methods or derivation of alternative activation pathways to expand freedom to operate.
References
[1] Beijing Tiantan Biological Products Co., Ltd. Patent CN121202730 (2022).
[2] Chinese Patent Database. IPC Classification and Patent Applications related to Antibody Processing.
[3] China National Intellectual Property Administration (CNIPA). Patent Landscape Reports on COVID-19 Therapeutics (2021-2022).
